<DOC>
	<DOCNO>NCT02634970</DOCNO>
	<brief_summary>There limited prospective data regard potential benefit risk associate switch anti-VEGF therapy patient nAMD initially achieve favorable response first anti-VEGF therapy use subsequently evidence increase disease activity despite continuation therapy . This study fill knowledge gap prospectively evaluate effectiveness safety switch aflibercept ranibizumab nAMD patient non - sustain response initial treatment aflibercept .</brief_summary>
	<brief_title>CANadian Study Patients With Wet AMD , Evaluating Efficacy Safety Switching From Intravitreal Aflibercept RanIbizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>BCVA ≥23 ETDRS letter study eye Screening Baseline visit . Evidence , Screening , active , angiographically confirm Choroidal Neovascularization ( CNV ) secondary AMD , directly indirectly affect center fovea study eye . No prior antiVEGF treatment aflibercept . History cerebrovascular accident , transient ischemic attack myocardial infarction within 3 month Screening visit . Any type systemic disease treatment , include medical condition ( control uncontrolled ) could expect progress , recur , change extent may bias assessment clinical status patient significant degree put patient special risk . Exclusion criterion ocular medical history condition either eye : Any active periocular ocular infection , active intraocular inflammation time Screening Baseline ( per contraindication Lucentis® Product Monograph ) . Uncontrolled glaucoma ( intraocular pressure [ IOP ] ≥30 mm Hg medication accord Investigator 's judgment ) time Screening Baseline Evidence bilateral active CNV Screening Period Baseline require bilateral antiVEGF injection . Prior intravitreal injection ranibizumab bevacizumab study eye and/or prior intravitreal injection bevacizumab fellow eye . Study eye exclusion criterion : At Baseline , intraocular surgery perform within previous 28 day intraocular surgery plan time 6 month study period Cataract ( cause significant visual impairment ) , aphakia , severe vitreous hemorrhage , rhegmatogenous retinal detachment , proliferative retinopathy choroidal neovascularization cause wet AMD ( e.g . ocular histoplasmosis , pathologic myopia ( ≥8 dioptre ) ) time Screening Baseline . Irreversible structural damage involve center fovea ( e.g . advanced fibrosis geographic atrophy ) opinion Investigator sufficient irreversibly impair visual acuity . Polypoidal choroidal vasculopathy ( PCV ) , RPE tear , central serous retinopathy ( CSR ) , significant vitreomacular traction identify Screening period within 4 month Baseline visit . Note small vitreomacular adhesion result deformity retina permit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>wet AMD , ranibizumab , aflibercept , neovascularization</keyword>
</DOC>